Personalis, Inc. Hits New 52-Week High of $18.88, Up 1292%

Personalis, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 18.88 on August 21, 2026. This achievement marks a remarkable performance over the past year, with the stock soaring by an impressive 1292.42%, significantly outpacing the S&P 500's growth of 20.47% during the same period. The company's market capitalization stands at USD 663 million, reflecting its position within the small-cap segment. Despite its recent price surge, Personalis, Inc. remains a loss-making entity, as indicated by its negative price-to-earnings ratio. The stock's price-to-book ratio is currently at 2.54, suggesting a valuation that may attract attention in the market. With a 52-week low of USD 4.65, the recent high underscores the volatility and potential for growth within the company. Investors and market watchers will be keen to observe how Personalis, Inc. navigates its future endeavors in the competitive biotechnology landscape.